Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: equities fell, not as far but, still down

September 13, 2019 7:15pm

… As the NASDAQ struggled

Trade, IP and tariffs resolution is all about saving “face”; the real issue in alleviating the “war” of barbs and words

It’s not hard to be right so often, it’s about refining expectation and defining insight

Don’t get comfortable, today’s market impacts Monday; If you were a subscriber … you would understand why! It's a daunting task to understand risk and seeing the unforeseen!

There are a variety of end uses to sector forecasts; the most prominent, they are used to protect your portfolio’s life and value.

Markets and indexes:

The Dow closed up +37.07 points or +0.14% to 27,219.52;
The S&P closed down -2.18 points or -0.07% at 3,007.39;
The NASDAQ was down -17.75 or -0.22% to 8,176.71;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Friday the IBB closed up +0.05% while the XBI also closed down -0.23%
Thursday the IBB closed down -0.61% while the XBI also closed down -0.75%
Wednesday the IBB closed up +1.78% while the XBI also closed up +1.65%
Tuesday the IBB closed up +1.15% while the XBI also closed up +2.47%
Monday the IBB closed down -0.41% while the XBI also closed down -0.15%

Henry’omics:

The Dow rose 1.6% week to date while the S&P 500 and NASDAQ both rose about 0.9%.

On the data front, consumer sentiment for September topped expectations as consumers felt better about the economy; however, worries over the trade war have increased.

This sector as part of the broader market is NOT investor based – it’s about electronic trading and its algorithms.

However, small caps are still being volume “played” by day traders whose loyalty is only to the cents made in trading – they’re travelers or tourists visiting for short periods.

The advance/decline line scenario of 45 covered companies:

Friday the close was negative with an A/D Line of 18/22 and 3 flats and 2 acquired;
Thursday the close was negative with an A/D Line of 17/26 and 0 flats and 2 acquired;
Wednesday the close was positive with an A/D Line of 26/15 and 2 flats and 2 acquired;
Tuesday the close was positive with an A/D Line of 31/10 and 2 flats and 2 acquired;
Monday the close was positive with an A/D Line of 25/18 and 0 flat and 2 acquired;

Decliners:

Regenxbio (RGNX -$1.64 after Thursday’s +$2.18);
Sage Therapeutics (SAGE -$1.11);
uniQure (QURE -$1.08);
Spark Therapeutics (ONCE -$0.88 after Thursday’s +$3.59);
Ionis Pharmaceuticals (IONS -$0.68 after Thursday’s +$2.05, Wednesday’s +$2.04, Tuesday’s+$2.67 and Monday’s -$1.63);

Incliners:

bluebird bio (BLUE +$1.74 after Thursday’s +$2.03, Wednesday’s-$0.71 and Tuesday’s +$2.14);
BioLife solutions (BLFS +$0.72);
Alnylam Pharmaceuticals ( ALNY +$0.52 after Thursday’s -$30.09, Wednesday’s +$1.90, Tuesday’s +$1.58 and Monday’s +$2.87;
Mesoblast (MESO +$0.48);
Fate Therapeutics (FATE +$0.48 after Thursday’s -$0.94, Wednesday’s -$0.71) after announcing an offering and its closing;

The percentage (%) indicators:

Friday’s range of the 18 upside was +0.40% (CLBS) to +8.25% (HSGX +$0.017) while the 22 downside ranged from -0.21% (BMRN) to -5.41% (ONVO);
Thursday’s range of the 17 upside was +0.20% (GBT) to +5.83% (RGNX) while the 26 downside ranged from -0.25% (BCLI) to -50.33% (ADVM);
Wednesday’s range of the 26 upside was +0.31% (ONCE) to +10.29% (KOOL) while the 15 downside ranged from -0.12% (HSGX -$0.003) to -3.72% (FATE);
Tuesday’s range of the 31 upside was +0.26% (BLFS) to +20.87% (MESO) while the 10 downside ranged from -0.44% (STML) to -11.66% (HSGX);
Monday’s range of the 25 upside was +0.22% (BLUE) to +16.81% (KOOL) while the 18 downside ranged from -0.25% (RENE.L) to -5.84% (AXGN);

Upside volume stats: to compare

Friday: 5 out of the 18 upside had higher than the 3 month average volume;
Thursday: 7 out of the 17 upside had higher than the 3 month average volume;
Wednesday: 10 out of the 26 upside had higher than the 3 month average volume;
Tuesday: 9 out of the 31 upside had higher than the 3 month average volume;
Monday: 10 out of the 25 upside had higher than the 3 month average volume;

Downside volume stats:

Friday: 6 out of the 22 downside had higher than the 3 month average volume;
Thursday: 6 out of the 25 downside had higher than the 3 month average volume;
Wednesday: 5 out of the 15 downside had higher than the 3 month average volume;
Tuesday: 7 out of the 10 downside had higher than the 3 month average volume;
Monday: 6 out of the 18 downside had higher than the 3 month average volume;

3 flat – BSTG, RENE.L and SLDB with 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed (SEPTEMBER?)

September’s sessions:

Friday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 17 advancers, 0 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 10 decliners, 31 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 18 decliners, 25 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 26 decliners, 16 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 11 decliners, 31 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday was Labor Day

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

7 hours 58 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.